Replies to post #129854 on Biotech Values

[iwfal]

Or perhaps FDA biosimilar guidance will be published soon as anticipated, and they can simplify everything but just negotiating a buyout by NVS ;)

Well, as I have said repeatedly - I hope not since, for example, if a buyout were to happen here it would probably be less than 35 which is substantially less than a fairly discounted NPV of what most people here would consider expected cash flow ('fairly' is this accounting is not picking a discount to make whatever price you want NPV to be.)